BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 27001944)

  • 1. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ST2: a new and promising activity marker in ulcerative colitis.
    Díaz-Jiménez D; Núñez LE; Beltrán CJ; Candia E; Suazo C; Alvarez-Lobos M; González MJ; Hermoso MA; Quera R
    World J Gastroenterol; 2011 May; 17(17):2181-90. PubMed ID: 21633527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
    Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.
    Kapsoritakis AN; Kapsoritaki AI; Davidi IP; Lotis VD; Manolakis AC; Mylonis PI; Theodoridou AT; Germenis AE; Potamianos SP
    BMC Gastroenterol; 2008 Nov; 8():55. PubMed ID: 19036126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
    Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
    Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
    Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
    World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum galectins as potential biomarkers of inflammatory bowel diseases.
    Yu TB; Dodd S; Yu LG; Subramanian S
    PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.
    Manolakis AC; Christodoulidis G; Kapsoritakis AN; Georgoulias P; Tiaka EK; Oikonomou K; Valotassiou VJ; Potamianos SP
    World J Gastroenterol; 2017 Jan; 23(3):437-446. PubMed ID: 28210079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
    Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
    Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
    Nikolaus S; Schulte B; Al-Massad N; Thieme F; Schulte DM; Bethge J; Rehman A; Tran F; Aden K; Häsler R; Moll N; Schütze G; Schwarz MJ; Waetzig GH; Rosenstiel P; Krawczak M; Szymczak S; Schreiber S
    Gastroenterology; 2017 Dec; 153(6):1504-1516.e2. PubMed ID: 28827067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum fetuin-A levels and active inflammatory bowel disease.
    Ma P; Feng YC
    Am J Med Sci; 2014 Jul; 348(1):47-51. PubMed ID: 24487480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.